[Treatment of myasthenia gravis with plasmapheresis (author's transl)].
Nine out of eleven severely ill patients with myasthenia gravis could be markedly improved by a combination of immunosuppressive drug therapy and plasmapheresis, two patients however suffered grave complications. The effectiveness of plasma exchange underlines the importance of plasma factors in the pathomechanism of myasthenic functional disturbance. Treatment with plasmapheresis may be regarded as a supportive measure of immunosuppressive drug therapy. However, the considerable risk and high technical requirements limit the indication to severe forms of the disease.
D000293:Adolescent; D000328:Adult; D001379:Azathioprine / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000188:drug therapy / Q000628:therapy*; D010956:Plasmapheresis; D011241:Prednisone / Q000627:therapeutic use
D003520:Cyclophosphamide; D001379:Azathioprine; D011241:Prednisone
Plasmapheresebehandlung bei Myasthenia gravis.